Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

A SARS-CoV-2 Infection Model in Mice Demonstrates Protection by Neutralizing Antibodies

Cell(2020)10.1016/j.cell.2020.06.011Source: DataRank Database

A SARS-CoV-2 Infection Model in Mice Demonstrates Protection by Neutralizing Antibodies is a research paper published in Cell (2020). On theSindex it has a DataRank of 0. It has been cited 578 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access578 citations

Download PDF

Cite:

Linked data & code

cellosaurus gen

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (24 grants)OA: bronzeTopics (60)Linked Datasets (22)DataCite Reuse (22)IDs (PubMed, PMC)Annotations (2)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (2/2)

Has DOI
Indexed in repositories

Accessible (1/2)

Open Access

Interoperable (2/2)

DataCite relations
Linked datasets

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (22)

James Brett Case ORCID,Emma S. Winkler ORCID,Larissa B. Thackray ORCID,Natasha M. Kafai ORCID,Adam L. Bailey ORCID

Live enrichment

PubMed:32553273 PMC:PMC7284254

NIAID NIH HHS

Grant: R01 AI127828

NIAID NIH HHS

Grant: R01 AI157155

NIAID NIH HHS

Grant: P01 AI060699

NHLBI NIH HHS

Grant: P01 HL152960

NIAID NIH HHS

Grant: R01 AI129269

NIAID NIH HHS

Grant: F30 AI152327

NIAID NIH HHS

Grant: R21 AI139813

NIAID NIH HHS

Grant: 75N93019C00062

NIAID NIH HHS

Grant: F32 AI138392

NIAID NIH HHS

Grant: R01 AI130591

NIAID NIH HHS

Grant: U01 AI141990

NIAID NIH HHS

Grant: HHSN272201400008C

NIEHS NIH HHS

Grant: P30 ES005605

NHLBI NIH HHS

Grant: R35 HL145242

NIAID NIH HHS

Grant: T32 AI007163

National Institutes of Health

Grant: 2U01AI141990-06

Programming Durable Immune Responses To Vaccination

National Institutes of Health

Grant: 5R01AI127828-05

Human neutralizing antibodies for Zika virus

National Institutes of Health

Grant: 5P01AI060699-10

Animal Core

National Institutes of Health

Grant: 5R01AI130591-02

PARP9-DTX3L Control Of Viral Infection and Airway Disease

National Institutes of Health

Grant: 5R35HL145242-02

Defining and Controlling Airway Disease

National Institutes of Health

Grant: 7F32AI138392-03

Analysis of factors controlling coxsackievirus population dynamics in the intestine

National Institutes of Health

Grant: 1R21AI139813-01

DIVISION OF LABOR IN HUMAN B CELL RESPONSES TO INFLUENZA VIRUSES

National Institutes of Health

Defense Advanced Research Projects Agency

bronzeLicense: Elsevier Non-Commercial

publisherhttp://www.cell.com/article/S009286742030742X/pdf

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/7284254

Europe_PMChttps://europepmc.org/articles/PMC7284254

Europe_PMChttps://europepmc.org/articles/PMC7284254?pdf=render

https://doi.org/10.1016/j.cell.2020.06.011

Fields of Study

0301 basic medicine03 medical and health sciences0303 health sciences

MeSH Terms

LungVero CellsAnimalsMice, Inbred BALB CMice, Inbred C57BLMice, Inbred DBAMice, KnockoutHumansMicePneumonia, ViralCoronavirus InfectionsDisease Models, AnimalPeptidyl-Dipeptidase AAntibodies, MonoclonalAntibodies, ViralImmunization, PassiveViral LoadTransduction, GeneticFemaleMaleAntibodies, NeutralizingHEK293 CellsPandemicsBetacoronavirusChlorocebus aethiopsCOVID-19Angiotensin-Converting Enzyme 2SARS-CoV-2

Keywords

MiceAntibodyAnimal modelInflammationPathogenesisPneumoniaCoronavirusCovid-19Sars-cov-2ResourceMaleAntibodies, ViralGeneral Biochemistry, Genetics and Molecular BiologyBetacoronavirusChlorocebus aethiopsAnimalsHumansLungMice, Inbred BALB CImmunization, PassiveAntibodies, MonoclonalAntibodies, NeutralizingMice, Inbred C57BLDisease Models, AnimalHEK293 CellsMice, Inbred DBAFemaleAngiotensin-Converting Enzyme 2Coronavirus Infections

Sustainable Development Goals

SDG 3: 3. Good health

Additional file 1 of Functional analysis of SARS-CoV-2 proteins in Drosophila identifies Orf6-induced pathogenic effects with Selinexor as an effective treatment

10.6084/m9.figshare.14313949.v1figshare

Additional file 1 of Functional analysis of SARS-CoV-2 proteins in Drosophila identifies Orf6-induced pathogenic effects with Selinexor as an effective treatment

10.6084/m9.figshare.14313949figshare

Additional file 1 of Integrative overview of antibodies against SARS-CoV-2 and their possible applications in COVID-19 prophylaxis and treatment

10.6084/m9.figshare.14471586.v1figshare

Additional file 1 of Integrative overview of antibodies against SARS-CoV-2 and their possible applications in COVID-19 prophylaxis and treatment

10.6084/m9.figshare.14471586figshare

Additional file 1 of Systematic identification of ACE2 expression modulators reveals cardiomyopathy as a risk factor for mortality in COVID-19 patients

10.6084/m9.figshare.18132780.v1figshare

Additional file 1 of Systematic identification of ACE2 expression modulators reveals cardiomyopathy as a risk factor for mortality in COVID-19 patients

10.6084/m9.figshare.18132780figshare

Additional file 9 of Systematic identification of ACE2 expression modulators reveals cardiomyopathy as a risk factor for mortality in COVID-19 patients

10.6084/m9.figshare.18132804.v1figshare

Additional file 9 of Systematic identification of ACE2 expression modulators reveals cardiomyopathy as a risk factor for mortality in COVID-19 patients

10.6084/m9.figshare.18132804figshare

Additional file 1 of Induction of high affinity monoclonal antibodies against SARS-CoV-2 variant infection using a DNA prime-protein boost strategy

10.6084/m9.figshare.20047238.v1figshare

Additional file 1 of Induction of high affinity monoclonal antibodies against SARS-CoV-2 variant infection using a DNA prime-protein boost strategy

10.6084/m9.figshare.20047238figshare

Additional file 2 of Induction of high affinity monoclonal antibodies against SARS-CoV-2 variant infection using a DNA prime-protein boost strategy

10.6084/m9.figshare.20047241.v1figshare

Additional file 2 of Induction of high affinity monoclonal antibodies against SARS-CoV-2 variant infection using a DNA prime-protein boost strategy

10.6084/m9.figshare.20047241figshare

Additional file 3 of Induction of high affinity monoclonal antibodies against SARS-CoV-2 variant infection using a DNA prime-protein boost strategy

10.6084/m9.figshare.20047244.v1figshare

Additional file 3 of Induction of high affinity monoclonal antibodies against SARS-CoV-2 variant infection using a DNA prime-protein boost strategy

10.6084/m9.figshare.20047244figshare

Additional file 4 of Induction of high affinity monoclonal antibodies against SARS-CoV-2 variant infection using a DNA prime-protein boost strategy

10.6084/m9.figshare.20047247.v1figshare

Additional file 4 of Induction of high affinity monoclonal antibodies against SARS-CoV-2 variant infection using a DNA prime-protein boost strategy

10.6084/m9.figshare.20047247figshare

Additional file 5 of Induction of high affinity monoclonal antibodies against SARS-CoV-2 variant infection using a DNA prime-protein boost strategy

10.6084/m9.figshare.20047250.v1figshare

Additional file 5 of Induction of high affinity monoclonal antibodies against SARS-CoV-2 variant infection using a DNA prime-protein boost strategy

10.6084/m9.figshare.20047250figshare

Additional file 6 of Induction of high affinity monoclonal antibodies against SARS-CoV-2 variant infection using a DNA prime-protein boost strategy

10.6084/m9.figshare.20047253.v1figshare

Additional file 6 of Induction of high affinity monoclonal antibodies against SARS-CoV-2 variant infection using a DNA prime-protein boost strategy

10.6084/m9.figshare.20047253figshare

Related Papers (10)

The monoclonal antibody combination REGEN-COV protects against SARS-CoV-2 mutational escape in preclinical and human studies

Cell(2021)

co-citedsame journal

10.1016/j.cell.2021.06.002

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

N/A

1.6DataRank · unranked

The Lancet(2020)

co-cited

10.1016/s0140-6736(20)30183-5

The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application

N/A

1.3DataRank · unranked

Annals of Internal Medicine(2020)

co-cited

10.7326/m20-0504

Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding

N/A

1.4DataRank · unranked

The Lancet(2020)

co-cited

10.1016/s0140-6736(20)30251-8

Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China

N/A

1.5DataRank · unranked

JAMA(2020)

co-cited

10.1001/jama.2020.2648

Potently neutralizing and protective human antibodies against SARS-CoV-2

N/A

14.8DataRank · unranked

Nature(2020)

co-cited

10.1038/s41586-020-2548-6

Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies

N/A

0.986DataRank · unranked

Nature Microbiology(2020)

co-cited

10.1038/s41564-020-00789-5

REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters

N/A

0.957DataRank · unranked

Science(2020)

co-cited

10.1126/science.abe2402

Engineered ACE2 receptor traps potently neutralize SARS-CoV-2

Proceedings of the National Academy of Sciences(2020)

co-cited

10.1073/pnas.2016093117

A Potently Neutralizing Antibody Protects Mice against SARS-CoV-2 Infection

N/A

0.812DataRank · unranked

The Journal of Immunology(2020)

co-cited

10.4049/jimmunol.2000583

A SARS-CoV-2 Infection Model in Mice Demonstrates Protection by Neutralizing Antibodies

FAIR Checklist

Authors (22)

Funding (24 grants)

Open Access

Topics

Linked Datasets (22)

Annotations (Europe PMC)

Related Papers (10)